Mifegyne (Mifepristone)

Mifepristone acts as a progesterone receptor antagonist. By blocking progesterone’s action on the uterine lining, it causes the decidua to break down and the gestational sac to detach, while also making the uterus more responsive to prostaglandins that promote expulsion of pregnancy tissue.

The dose of Mifegyne is determined by the prescribing clinician based on the patient’s clinical situation, gestational age, and local treatment protocols. Only a qualified health professional can set the appropriate regimen, which may involve a single tablet followed by a prostaglandin medication.

Mifegyne is intended for use in early pregnancy to terminate a confirmed intra‑uterine gestation; it is not used to treat ongoing pregnancy. Breastfeeding is generally not recommended until the medication is fully cleared from the body, and patients should discuss any concerns with their health care provider.

To order Mifegyne, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Mifegyne (mifepristone) is the most widely used progesterone receptor antagonist for medical abortion, often combined with misoprostol. Compared with regimens that rely solely on prostaglandins, the mifepristone‑misoprostol combination offers higher efficacy, shorter treatment duration, and a more predictable outcome.

Mifegyne tablets should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and store out of reach of children to maintain potency and safety.

Mifegyne is taken orally as a tablet, usually in a single dose under the supervision of a qualified health professional. After ingestion, a prostaglandin analogue such as misoprostol is often prescribed to complete the termination process, following the clinician’s protocol.

Serious risks, though uncommon, include severe hemorrhage requiring medical intervention, infection indicated by fever or foul discharge, and rare allergic reactions such as anaphylaxis. Patients should be monitored closely and instructed to seek immediate medical care if any of these signs occur.

Mifegyne should not be used by individuals with chronic adrenal failure, those on long‑term corticosteroid therapy, patients with known hypersensitivity to mifepristone, or anyone with contraindicated medical conditions such as uncontrolled bleeding disorders. A thorough medical assessment is required before prescribing.